The prospective drug use review program must be based on the guidelines established by the Department of Human Services in consultation with the Drug Use Review Board. The program must provide that prior to the prescription being filled or delivered a review will be conducted by the pharmacist at the point of sale to screen for potential drug therapy problems resulting from the following:
(1) Therapeutic duplication.
(2) Drug-drug interactions, including serious interactions with nonprescription or over-the-counter drugs.
(3) Incorrect dosage and duration of treatment.
(4) Drug-allergy interactions.
(5) Clinical abuse and misuse.
(6) Drug-disease contraindications. [1993 c.578 §13]
Note: See note under 414.350.Section: Previous 414.346 414.348 414.350 414.355 414.360 414.365 414.370 414.375 414.380 414.385 414.390 414.395 414.400 414.410 414.415 Next
Last modified: August 7, 2008